NEW YORK (TheStreet) -- Achillion Pharmaceuticals  (ACHN) - Get Report  surged to a 52-week high of $11.15 in afternoon trading Monday after UBS tabbed the company as a possible takeover target.

Roche's $8.3 billion bid for InterMune  (ITMN) led the biotech sector up on Monday. In the wake of the news, UBS highlighted Achillion as another potential merger and acquisition target.

"While we had viewed InterMune as a top take-out candidate in biotech, we also note our Buy rating on Achillion Pharmaceuticals shares also reflects M&A potential," the firm wrote, according to Barron's.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 11.81% to $10.91 at 2:20 p.m. More than 10 million shares had changed hands, compared to the average volume of 7,447,590.

Image placeholder title

ACHN

data by

YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.